Sign in

    Li Watsek • Cantor Fitzgerald

    Li Watsek's questions to Kura Oncology Inc (KURA) leadership

    Li Watsek's questions to Kura Oncology Inc (KURA) leadership • Q2 2025

    Question

    Li Watsek asked for Kura's perspective on the competitor's Menin inhibitor launch in KMT2A-rearranged AML and sought details on the progress of Kura's Phase 3 frontline trials, including the company's confidence in achieving a first-in-class position.

    Answer

    Chief Commercial Officer Brian Powl stated that while the competitor's launch is positive for patients, Kura is confident in Zifdomenib's potentially best-in-class profile. Chief Medical Officer Dr. Mollie Leoni highlighted that the COMET-seventeen protocol's single design for two trials is attractive to sites, expressing high confidence in a second-half 2025 start and robust enrollment.

    Ask Fintool Equity Research AI

    Li Watsek's questions to Zai Lab Ltd (ZLAB) leadership

    Li Watsek's questions to Zai Lab Ltd (ZLAB) leadership • Q2 2025

    Question

    Li Watsek of Cantor Fitzgerald inquired about the remaining steps required to file bemarituzumab in China and the potential timing for an NRDL listing. She also asked for Zai Lab's perspective on upcoming data from a competitor's DLL3 program and what additional information Zai Lab plans to share in its next data update for its own DLL3 ADC.

    Answer

    Josh Smiley, President & COO, stated that the immediate focus for bemarituzumab is securing regulatory approval, after which they will pursue NRDL listing as quickly as possible. Rafael Amado, President and Head of Global R&D, added they are working with partner Amgen to submit expeditiously. Regarding the DLL3 ADC, Dr. Amado expressed confidence in their asset's best-in-class profile and confirmed the next data update will include more follow-up on response durability, PFS, and a detailed analysis of intracranial activity.

    Ask Fintool Equity Research AI

    Li Watsek's questions to Zai Lab Ltd (ZLAB) leadership • Q4 2024

    Question

    Li Watsek questioned the expected durability of ZL-1310 compared to other modalities and the plan for its confirmatory study. She also asked for a Q4 breakdown of new versus maintenance patients for VYVGART and their expected future contribution.

    Answer

    Dr. Rafael Amado, President and Head of Global R&D, explained it was too early for median durability data on ZL-1310 but noted its efficacy appears independent of prior chemo sensitivity. Joshua Smiley, President and COO, addressed the VYVGART question, stating new patient initiations are around 1,000 per month, with an increasing number starting in the maintenance phase. He cited that 40% of patients who started in Q3 2023 had already returned for a second cycle in Q4 2023.

    Ask Fintool Equity Research AI

    Li Watsek's questions to Arvinas Inc (ARVN) leadership

    Li Watsek's questions to Arvinas Inc (ARVN) leadership • Q2 2025

    Question

    Li Watsek inquired if a priority review should be anticipated for the Vepdeq NDA submission and asked about the global filing strategy. She also asked about the key considerations Arvinas would prioritize when seeking a potential new partner for Vepdeq to maximize its value.

    Answer

    CEO John Houston stated they are awaiting details from the FDA on the PDUFA date and will share them once available. CMO Noah Berkowitz added that they have not yet offered guidance on a global filing strategy. Regarding a new partner, Houston emphasized the goal is to place Vepdeq with a company, be it Pfizer or another, that is committed to launching, commercializing, and funding further development of the asset globally, with minimal future development involvement from Arvinas.

    Ask Fintool Equity Research AI

    Li Watsek's questions to Arvinas Inc (ARVN) leadership • Q1 2025

    Question

    Li Watsek asked about Arvinas's business development strategy regarding in-licensing external assets, the company's conviction in its early-stage pipeline, and the expected timing and success bar for the KAT6 combination data.

    Answer

    CEO John Houston explained that while Arvinas is a platform-driven company, it remains open to in-licensing an asset that complements its lead programs. CMO Noah Berkowitz clarified that the KAT6 combination is an exploratory, all-comer Phase 1 trial run by Pfizer with no set timelines for data, as it is just beginning.

    Ask Fintool Equity Research AI

    Li Watsek's questions to Corvus Pharmaceuticals Inc (CRVS) leadership

    Li Watsek's questions to Corvus Pharmaceuticals Inc (CRVS) leadership • Q4 2024

    Question

    Representing Li Watsek, an analyst inquired about Corvus's strategy for prioritizing soquelitinib's development between oncology and inflammatory diseases as it moves to later-stage trials. A follow-up question asked if the delayed presentation of Cohort 4 data was due to enrollment issues or a decision to await Cohort 3 results.

    Answer

    Executive Richard Miller clarified that the strategy is to 'push on all fronts aggressively' to secure approvals in both lymphoma and immune diseases, citing Rituxan as a precedent for a drug used in both areas. He noted that at the right time, the company would consider a partnership for the vast autoimmune disease opportunity. Regarding Cohort 4, Miller confirmed there is 'no delay in enrollment' and the company is simply waiting to see the full data from Cohort 3 before making a final decision.

    Ask Fintool Equity Research AI

    Li Watsek's questions to Arcus Biosciences Inc (RCUS) leadership

    Li Watsek's questions to Arcus Biosciences Inc (RCUS) leadership • Q1 2024

    Question

    An analyst from Cantor Fitzgerald & Co., on for Li Watsek, asked about pipeline prioritization. She inquired how Arcus is thinking about its next-generation programs, including its inflammation portfolio, while simultaneously executing on multiple late-stage oncology trials.

    Answer

    CEO Terry Rosen explained that the collaboration with Gilead was designed to function as an R&D engine, enabling continued investment in discovery alongside late-stage development. He highlighted the AXL inhibitor as a notable early-stage program that recently entered the clinic. Rosen also mentioned that while the company has a strong immunology biology group and will likely increase its focus on immunology and inflammation (I&I), the primary driver for new projects remains identifying the best targets, regardless of therapeutic area.

    Ask Fintool Equity Research AI